developments in clinical biochemistry volume 2

# G. Siest, editor DRUG EFFECTS ON LABORATORY TEST RESULTS

## DRUG EFFECTS ON LABORATORY TEST RESULTS

Proceedings of a Workshop on 'The Use of Laboratory Test Results. Variations due to Drug Intake' sponsored by the Commission of the European Communities, as advised by the Committee on Medical and Public Health Research and held at the Abbaye des Prémontrés, Pont-à-Mousson (France), December 17-19, 1979

#### editor

G. SIEST, Nancy, France

#### co-editors

J.G. SALWAY, Guildford, United Kingdom

D. REEDER, Washington, USA

N. TRYDING, Kristianstad, Sweden

C.A. DUJOVNE, Kansas City, USA

F.W. SUNDERMAN, Farmington, USA

#### executive editor

D. NOTTER, Nancy, France



1980

MARTINUS NIJHOFF PUBLISHERS THE HAGUE / BOSTON / LONDON

for

THE COMMISSION OF THE EUROPEAN COMMUNITIES

Distributors:

for the United States and Canada Kluwer Boston, Inc. 190, Old Derby Street Hingham, MA 02043 USA DRUG EFFECTS ON LABORATORY TEST

2Notibaser.

McGarlined Lines Knadom

28 THEFT REST TRACELLY

THE COMMISSION OF THE PURCH AN COMMINGETT S

D. BEEDER, Washington, USA

for all other countries

Kluwer Academic Publishers Group

Distribution Center

P.O.Box 322

3300 AH Dordrecht

The Netherlands

Library of Congress Cataloging in Publication Data

CIP

Main entry under title:

Drug effects on laboratory test results.

(Developments in clinical biochemistry; v. 2)

1. Chemistry, clinical—Congresses. 2. Drugs—Physiological effect—Congresses. 3. Drugs—Side effects—Congresses. I. Siest, G. II. Commission of the European Communities. III. Commission of the European Communities. Committee on Medical and Public Health Research. IV. Series [DNLM: 1. Drugs—Analysis—Congresses. 2. Drugs—Metabolism—Congresses. 3. Chemistry, Clinical—Congresses. W1 DE997VR v. 2 / QY90 D794 1979]

RB49.D78

616.07'56

80-24263

ISBN 90-247-2419-8 (this volume) ISBN 90-247-2335-3 (series)

Publication arranged by: Commission of the European Communities, Directorate-General Information Market and Innovation, Luxembourg

**EUR 6860 EN** 

Copyright © ECSC, EEC, EAEC, Brussels-Luxembourg, 1980

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher,

Martinus Nijhoff Publishers bv, P.O.Box 566, 2501 CN The Hague, The Netherlands.

#### LEGAL NOTICE

Neither the Commission of the European Communities nor any person acting on behalf of the Commission is responsible for the use which might be made of the following information.

PRINTED IN THE NETHERLANDS

### DRUG EFFECTS ON LABORATORY TEST RESULTS

FOLUME 2

Other Miles in this series

1. R. Melyano, ed., Impunospot water Assay Tes ISBN 90-267-2314-0

Series 1880s: 90-243/8355-3

#### **VOLUME 2**

#### Other titles in this series

 R. Malvano, ed., Immunoenzymatic Assay Techniques. 1980 ISBN 90-247-2314-0

Series ISBN: 90-247-2335-3

#### PREFACE

This book constitutes the Proceedings of a Workshop held at Pont-à-Mousson under the aegis of the Committee of Medical Research and Public Health (CRM) of the Commission of European Communities.

After some introductory presentations, the different papers on drug effects concern four main themes:

- analytical interferences
- drug effect on specific laboratory tests
- physiological or toxical effects
- general pharmacological effects

Drugs and xenobiotics can increase or decrease the level of certain blood constituents. This effect may be desirable or not. It can be due to an analytical or to a pharmacological effect. It is necessary after such workshop to prepare detailed technical protocols for the two types of effects on laboratory tests.

The "in vitro" effects, called analytical interferences, have to be systematically checked, especially for chemical tests. There are likely to disappear with further progress in analytical methods towards specificity.

The "in vivo" pharmacological effects of drugs must be measured and calculated for every new drug or new laboratory method. The knowledge of these effects in terms of percentages will permit a better interpretation of laboratory results by physicians and clinical biochemists.

A consensus was established between the different participants of the workshop to emphasize the necessity of having a data bank on drug interferences and drug effects in clinical chemistry. This bank should also enclose information concerning the influence of other biological variation factors. Contrarily to the existing data banks, the new one should be filled up with validated information from the literature. It would be open for general practitioners, clinical chemists, pathologists, pharmaceutical industries... to better interpret laboratory results and diminish the incorrect diagnoses and mistreatment of patients.

We thank all those individuals who contributed to the efficiency and success of the meeting, as chairmen or secretaries of the scientific sessions. We wish also to thank Chantal Thirion for the general secretariat organisation of the meeting and the proceedings.

Gérard SIEST

HATTENED R.

#### D STEADERSON SOLE SE A LIST OF PARTICIPANTS US I SENDENTE

Klinische Hothschule Bannover, Karl Mischert Aline H.

- BACHMANN, C. Insclspital Bern, Chemisches Zentrallabor der Universitätskliniken, CH-3010 BERN (Switzerland)

  BAGREL, A. Laboratoire d'Hygiène, Faculté des Sciences Pharmaceutiques
- BAGREL, A. Laboratoire d'Hygiène, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebrun 54000 NANCY (France)
- BAGREL, D. Laboratoire de Biochimie Pharmacologique, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebrun 54000 NANCY (France)
- BATT, A.M. Laboratoire de Biochimie Pharmacologique, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebran 54000 NANCY (France)
- BRAQUET, P. Laboratoires FOURNIER, B.P.130, 21004 DIJON Cedex (France)
- CASTILLO DE Torres Adaid ≠ 508, Col Del Valle, MEXICO D.F., Mexico SANCHEZ M.L. ZP 12 (Mexico)
- DELATTRE, J. Faculté de Pharmacie, 28 Place Henri Dunant, B.P. 38 63001 CLERMONT FERRAND Cedex (France)
- DELWAIDE, P. Université de Liège, Laboratoire de chimie médicale, rue des Bonnes Villes, B 4020 LIEGE (Belgium)
- DUJOVNE, C.A. University of Kansas Medical Center, College of Health Sciences and Hospital,
  Clinical Pharmacology Toxicology Center,
  Rainbow Bd AT 39TH, KANSAS CITY, KANSAS 66103 (USA)
- FERRAND, C. Laboratoire PARCOR, Département de Biologie Clinique, 195 Route d'Espagne, 31300 TOULOUSE (France)
- GALIMANY, R. Departemento de analisis clinicos, Hospitalet de Llobregat, BARCELONE (Spain)
- GALLI, A. Service de Biochimie, Hopital de la Salpêtrière, 47 Bd de l'Hopital, 75634 PARIS Cedex 13 (France)
- GALTEAU, M.M. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot, 54500 VANDOEUVRE LES NANCY (France)
- GASPART, E. 48 Bd Docteur E.Feltgen, LUXEMBOURG (Grand Duché)
- GILLET, M. Communauté Européenne, 200 rue de la Loi, 1040 BRUXELLES (Belgium)
- GUELFI, J.F. Ecole Nationale Vétérinaire, 23 Chemin des Capelles, 31076 TOULOUSE Cedex (France)

Klinische Hochschule Hannover, Karl Wiechert Allee 9, HAECKEL, R. 3 HANNOVER 61 (German Federal Republic) Finseinstitutet, Strandboulevarden 49, 2100 COPENHAGUE Ø HENDEL, J. (Denmark) HENNY, J. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot, 54500 VANDOEUVRE LES NANCY (France) HIMBERG, J.J. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, 00290 HELSINKI 29 (Finland) Laboratoire de Biochimie Pharmacologique, Faculté des HITZ, J. Sciences Pharmaceutiques, 7 rue Albert Lebrun 54000 NANCY (France) HOUOT, O. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot, 54500 VANDOEUVRE LES NANCY (France) HUBSCH, G. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot, 54500 VANDOEUVRE LES NANCY (France) Commission of European Communities, Biology Division D.G. XII 21020 ISPRA (Italy) LIEWENDAHL, K. Department of Clinical Chemistry, University Central Hospital, HELSINKI (Finland) LOVE, C. Department of Biochemistry, Trinity College, Dublin University, DUBLIN 2 (Ireland) MAHASSEN, A. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot, 54500 VANDOEUVRE LES NANCY (France) MORIN, C. 13 Avenue Foch, 54000 NANCY (France) Laboratoire de Pharmacodynamie, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebrun 54000 NANCY (France) RATANASAVANH, D. Recherche Biologique et Pharmaceutique Lorraine, 7 rue Albert Lebrun 54000 NANCY (France) REEDER, D. Chemistry Building, National Bureau of Standards, WASHINGTON, DC 20234 (USA) Laboratoire SYNTHELABO, 6 Boulevard Emile Zola REGNIER, F. 54520 LAXOU (France) Institute of Pathology, Department of Clinical Biochemis-ROGULSKI, J. try, Medical Academy, Debinki 7, GDANSK (Poland) SALWAY, J. University of Surrey, Department of Biochemistry, GUILDFORD, SURREY GU2 5XH (England)

- SARHAN, N. Laboratoire de Biochimie Pharmacologique, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebrun 54000 NANCY (France)
- SCHEUCH, D.W. Medizinische Akademie "Carl Gustav Carus", Fetscherstrasse 74, 8019 DRESDEN (German Democratic Republic)
- SCHIELE, F. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot 54500 VANDOEUVRE LES NANCY (France)
- SIEST, G. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot 54500 VANDOEUVRE LES NANCY et Laboratoire de Biochimie Pharmacologique, Faculté des Sciences Pharmaceutiques et Biologiques, 7 rue Albert Lebrun 54000 NANCY (France)
- STEINMETZ, J. Laboratoire du Centre de Médecine Préventive, 2 Avenue du Doyen Jacques Parisot 54500 VANDOEUVRE LES NANCY (France)
- SUNDERMAN, F.W. Department of Laboratory Medicine, University of Connecticut, School of Medicine, Box G. FARMINGTON, CONN.06032
- TAZI, A. 26 rue 251 bis, AIN-KADDOUS, FES (Marocco)
- TOGNONI, G. Istituto di Ricerche Farmacologiche, "Mario Negri", Via Eritrea, 62 - 20157 MILANO (Italy)
- TRIVIN, F. Service de Biochimie, Hopital Saint Joseph, 7 rue Pierre Larousse, 75674 PARIS Cedex 14 (France)
- TRYDING, N. Centralsjukhuset, 291 85 KRISTIANSTAD (Sweden)
- VASSEUR, P. Institut Européen d'Ecologie, 57000 METZ (France)
- WINKEL, P. Finseninstitutet, Strandboulevarden 49, 2100 COPENHAGUE  $\emptyset$  (Denmark)

#### CONTENTS

| Preface G. Siest  | And adjusted the second control of the second secon |                  |
|---|--|------------------|
| List of participants  |  | XI               |
| List of participants  |  |                  |
| Ĩ   |  | 334              |
| L .   |  | n 6              |
|   |  | Servery A. I.    |
| BASIC PROBLEMS  |  |                  |
|   |  | 14               |
|   |  | 7.               |
|   | lrug effects in clinical biochemistry  | 3                |
| G. Siest, M.M. Galteau and D.                                     | Notter   | 7-10-24 E        |
| Clinica pharmacological problem                                   | s in the evaluation of side effects of drugs   | 14               |
| E Colombo and G Tognoni   | is in the evaluation of side effects of drugs  | office Burgerrol |
| r. Colombo ana G. Tognom  | tolin C. Tirya and to her  | 100 100          |
| A new file for clinical use in the N. Tryding, S.G. Johansson and | s on drug effects in clinical chemistry.  computerized Swedish drug information system  nd P. Manell   | m 27             |
| The second of the second of                                       | et a gran var e e e marin a Louis Zualie.  |                  |
| *   | was a section only on may bee 500 set  |                  |
| ANALYTICAL INTERFERENC  | EC   | 17,385           |
| ANALY HEAL INTERPERENC  |  |                  |
|   |  |                  |
| Analytical interferences of drugs                                 |  | 39               |
|   | or action long views to the love with many state of the  | rsanhri rai      |
|   | 5 Designated Integration on the links of drawing   |                  |
|   | reference methods in the evaluation of drug ef   |                  |
| D.J. Reeder   |  |                  |
| the sent in real manufactor gur                                   | and seattlemental and the seattless of the   | lprod-randi      |
| Detection of drug interferences i<br>R. Haeckel and O. Sonntag    | in method evaluation programs  | 58               |
|   | . Typik ishi asarraga x. Te; "Tuyu Terrilma;   |                  |
| Analytical interferences due to a R. Galimany                     | ntiinflammatory drugs  | 74               |

95.

#### DRUG EFFECTS ON LABORATORY TESTS

| Drug effects on laboratory tests: uric acid  J.G. Salway   | 85     |
|--|--------|
| Effects of drugs on total serum cholesterol  J. Delattre and P. Bastide  | 91     |
| Drug effects on cholesterol plasma lipoproteins fractions P. Braquet and M. Braquet  | 99     |
| Effects of drugs and physiological substances on serum and urine creatinine  J. Rogulski and A. Pacanis  | 134    |
| Drug effects on hematological tests  J.F. Guelfi   | 146    |
|  |        |
| PHYSIOLOGIC OR TOXIC EFFECTS   |        |
| Interpretation of laboratory tests: the example of drug effects on aminotransferases  M.M. Galteau, C. Morin and G. Siest  | 159    |
| On the influence of phenylhydrazine and related compounds on the activity of enzymes D. W. Scheuch   |        |
| Laboratory tests as indirect indicators of the activity of drug metabolizing enzymes: use of glucaric acid and gamma-glutamyltransferase  A.M. Batt and G. Siest   | 178    |
| Drug effect on vitamin levels  JJ. Himberg   | 193    |
| The second of th | miny   |
| The interaction between antiepileptic therapy and folate absorption and distribution.  A kinetic approach to obtain more meaningful laboratory data  | 206    |
| J. Hendel, P. Winkel and M. Dam  |        |
| Differentiation of toxic from spurious abnormalities after drug administration in man C.A. Dujovne   | 214    |
| Effects of xenobiotics on heme oxygenase activity  | 221    |
| F.W. Sunderman agreein section of the section of th | ivi un |

TWENTO'

|  |                 | VII   |
|--|-----------------|-------|
| Use of laboratory tests for estimation of patients' alcoholic intake  A. Bagrel, B. Herbeth and D. Barrucand |                 | 236   |
|  |                 | 4     |
| Effects of drugs on thyroid function tests  K. Liewendahl  |                 | 245   |
| K. Liewendani  |                 |       |
|  |                 |       |
|  |                 |       |
| PHARMACOLOGICAL EFFECTS  | 18              |       |
|  |                 |       |
| Effects of antiepileptic drugs on laboratory tests  D. Bagrel, A. Bagrel, B. Le Perron and G. Siest          |                 | 261   |
|  |                 | 92617 |
| Pharmacological effects due to oral contraceptives on laboratory tests<br>F. Schiele and G. Siest            | 1,24            | 274   |
| Pharmacological effects due to hypolipidemic drugs  J. Steinmetz, E. Gaspart and D. Notter                   | and application | 295   |
| Pharmacological effects of tranquilizers and laboratory tests interference F. Trivin and M.F. Gerhardt       | es              | 304   |
| F. Trivin and M.F. Gernarat  | 3.00            | , 'N  |
| Effect of imipramine on laboratory tests   |                 | 312   |
| A. Tazi, M.M. Galteau and G. Siest   |                 |       |

#### BASIC PROBLEMS

G. Siest, M.M. Galteau and D. Notter

Faculté des Sciences Pharmacologique ERA CNRS 698

7, rue Albert Lebrun 54000 NANCY France

#### ABSTRACT

Drugs and xenobiotics can increase or decrease the level of certain blood constituents. This effect may be desirable or not. It can be due to an analytical or to a pharmacological effect.

The "in vitro" effect, called analytical interference, has to be systematically checked, especially for chemical tests. It is likely to disappear with further progress in analytical methods towards specificity.

The "in vivo" pharmacological effects of drugs must be measured and calculated for every new drug or new laboratory method. The knowledge of these effects in terms of percentages will permit a better interpretation of laboratory results by clinical chemists and physicians.

Laboratory tests can be used, in addition, to monitor drug effects. The authors rapidly describe the usefulness of laboratory tests in this field. The general introduction clearly shows that it is now necessary to prepare technical protocols for analytical interferences and pharmacological effects. It is obvious that international recommendations must be writen in order to collect information. All this work will be grouped in the next future into a data bank on drug effects. Clinical chemists, physicians... will improve the interpretation of laboratory test results in treated people by consulting this bank.

#### INTRODUCTION

Clinical chemists, clinicians and drug manufacturers are increasingly aware of the problems related to the effects of drugs on laboratory tests (Siest et al., 1980). These effects can assume several aspects:

- a purely analytical aspect, in which the drug and/or its metabolites can perturb the assay of a constituent at any stage; in clinical chemistry, the term "interference" can be reserved for this "in vitro" effect;
- a biological aspect, in which the drug provokes a change in a biological parameter by a physiological, pharmacological or toxicological mechanism. This second aspect constitutes what can be called the unexpected secondary effects of drug, desirable or not.

Laboratory tests exploring the liver, the kidney, etc, may be carried

out for a person who, without the knowledge of the physician ordering the tests, takes tranquillizers, hypnotics, or oral contraceptives... So it is very important to know exactly the sort of drug taken by a patient and the exact conditions of administration. It is hopeful to get a precise question-naire which can be filled at the same time the blood is drawn. The figure I presents an example of sampling form.

| 3               | ORGANISATION REGIONALE DES EXAMENS DE SANTE   |                         |
|-----------------|---|-------------------------|
| N. V            |   | Date                    |
| 1.3             | Surname   | c.c. 599                |
| N.              | First name Lab. N°  | Court as a part of land |
| Wir ed men      | Age Years Months Individual N°  | was an arminist         |
|                 | Sex:<br>N° Nurse: Islai Isatiylun, ballus assili  | Service of Son          |
| No. of Sections | Time of blood sampling  |                         |
| WELL THE ST.    | Are you fasting ? Don't out   100 | tern maleral dille      |
|                 | 1: If yes If no: 2 - breakfast 3 - meal at center (700 cal.)  | to "owle no" not        |
| D Ministra      | 3 - meal at center (700 cal.)   | range and both          |
|                 |   |                         |
| ama eastanau    |   | 10.00 01.00 03.00       |
|                 | Gynaecology : Vidy Eng 1338 man . Healers . wit   |                         |
| dell'in smi     | Cycle 1 Pregnancy 2 Menopause 3 Other cases 4   | man Roccingor.          |
| rin or new      | Date of first day of last period :  | Day Month               |
| ELBATT DODA     | Since when do you smoke (in number years) ?<br>Have you smoked within the last two hours ?  | of femous set           |
| Loamrado        | Are you taking the "pill" ?   | loan Later and h        |
| nd treom t      | Have you taken medicines°?<br>Sampling not possible°  | de alesta parel         |
| in i hagina     | Weight :  | o Lincoln repried       |
| esvio sis       | Laboratory : Total Date, still girth man high s   |                         |
|                 | Serum de de des de la relatable de la   |                         |
| represit t      | W   |                         |
|                 | Plasma appearance   | TIC MID TIMESON I       |
| 1               | Normal 0 Lactescent 4 [cteric and opalescent 8  |                         |
| }               | Opalescent 2 Icteric 5 Various (carotenoids) 9  | _                       |
|                 | °l if yes   |                         |

Fig. I : Sampling sheet

The drug intake questionnaire (Fig. 2) is used only if the patient has answered "yes" to one of the questions about drugs on the sample sheet.

Laboratory tests are also playing an increasingly important part in the monitoring of drug treatments. So far such tests have mainly been used only to evaluate the efficiency of treatments (with hypoglycemic agents, hypolipemic agents, anticoagulants, etc.). More recently, biological tests for such substances as triacylglycerols (triglycerides) have been more and more commonly used in the surveillance of patient taking oral contraceptives. Now a new chapter is beginning i.e. laboratory tests are used as indices of the activity of drug-metabolizing enzymes, particularly for their

|   | - VETEL FILL TEXTORY BETSER  |
|---|--|
| all of oakd                                 | ORGANISATION REGIONALE DES EXAMENS DE SANTE  |
| 3.0   | District Control of the Control of t |
| With  | d compared to the compared to  |
| A Y   | Surname  |
| W   | First name Lab. Nº   |
| nest un vivo                                | BETTERNET STEED STEED TO INDIVIDUAL N° I CONTRACTOR SHT -  |
| 1   | - Are you taking medecines as part of a long-term treatment 1:YES 2:NO -   |
| reling of bounds                            | of the standard of the standar |
| 2   | Names Names  |
| nda artariahasiin                           | s par nelvolutes est a st. (ujeau ad ) (ud ) () . ( Pinist s   |
| are builty pro-                             | S miles compared a material and service constitution of the  |
|   | - Have you taken medicines in exceptional [OSE1 , 87x2087 [19] 08  |
|   | circumstances (during the last 48 hours)   |
|   | If yes, which ?  |
| heart district set                          |  |
| g'growy ri bon.                             | Names  |
| 1   | The server and the server and the  |
| mer sport as-                               | The can be due to the free light of to it settled it   |
| 1   | - Have you undergone a long-term treatment (more and long-term treatment)  |
|   | than 3 months) which you have since stopped ?  |
| Space mit us                                | 1 - less than I month 2 - I week to I month  |
|   | 3 - 1 to 6 months and an analysis to bless the a dr bum to tag a   |
| on should be av                             | - Have you already taken the "pill" ? I set useful as as more Traumiliyes 2:NO   |
| and he some a                               | If no, you are not concerned by the following I THERE BY THOUSE OF   |
| v   | - You take contraceptive pills:  . Since when ?  Year Month  |
|   | . Which pill are you using now ?   |
| nassidat Supe-                              | 01 Anovlar 10 Ovariostat 24 Trentovlane<br>02 Gynophase 11 Ovulene 50 31 Norquentiel   |
|   | 03 Gynostat 12 Ov 28 32 Ovanon   |
| beat waveleup                               | 04 Gynovlane 13 Planor 33 Physiostat 05 Lyndiol 14 Relovis 41 Exluton  |
| new the man has                             | 06 Metrulene 15 Stediril 42 Microval<br>07 Millianovlar 21 Adepal 43 Milligynon  |
|   | 08 Noracycline 22 Minidril   |
| FEET 11 11 12 12 12 12 12 12 12 12 12 12 12 | 09 Nov 50 23 Hinipnase and particular and the second secon |
| zno Ladumeli, ku                            | . Have you changed the kind of pill ? 1:YES 2:NO - Old pill :  |
| . Strellerin                                | Length of time taken (in months) :   |
|   | Length of time taken (in months) :   |
| VI  | - Have you stopped taking the pill ? 1:YES 2:NO If yes, since when (in months) :   |
| -otom n. Insta                              | Name of pill which you took :  |
| Total Total                                 | The two factories constant will send done that refine ways age-  |

Fig. 2 : Questionnaire on the intake of drugs

试读结束,需要全本PDF请购买 www.ertongbook.com